Valproate Loading Dose Regimen and Maintenance

Post-Loading Dose Maintenance Strategy

For status epilepticus, an IV loading dose of 20 mg/kg is given over 10 minutes, with a repeat dose of 20 mg/kg possible after 15 minutes if seizures persist, according to the Pediatrics guideline 1
The target therapeutic serum concentration for bipolar disorder is 40-90 mcg/mL, as recommended by the Praxis Medical Insights guideline 2

Check serum valproate level within 48-72 hours after loading to confirm therapeutic range, as recommended by the Praxis Medical Insights guideline 3
Monitor liver enzymes at baseline and regularly throughout treatment, according to the Praxis Medical Insights guideline 2
Monitor complete blood count, especially platelets, as recommended by the Praxis Medical Insights guideline 3

For status epilepticus, an IV loading dose of 20 mg/kg over 10 minutes may be repeated once after 15 minutes if seizures continue, with a maximum total dose of 40 mg/kg, according to the Pediatrics guideline 1
The efficacy rate of valproate for status epilepticus is 63-88%, as reported by the Praxis Medical Insights guideline 3

Neonates have an increased risk of toxicity due to decreased protein binding, and phenobarbital is preferred in this population, according to the Pediatrics guideline 1

Dividing doses reduces gastrointestinal side effects compared to single daily dosing, as reported by the Annals of Emergency Medicine 4

The American College of Emergency Physicians recommends an initial loading dose of 20-30 mg/kg IV infused over 10 minutes for status epilepticus, with a maximum infusion rate of 10 mg/kg/min 5
The expected efficacy rate for terminating status epilepticus is 63-88% 6
Valproate can be administered more rapidly with fewer adverse cardiovascular effects compared to phenytoin/fosphenytoin, and has a lower incidence of hypotension and cardiac dysrhythmias 6
Valproate has no risk of soft tissue injury from extravasation, unlike phenytoin 6

Common side effects during/after loading include transient local irritation at injection site 5, dizziness, and nausea (generally mild) 6
Serious but rare complications include thrombocytopenia (monitor platelets) 6, hepatotoxicity (monitor liver enzymes) 6, and hyperammonemia 6
Valproate causes significantly less hypotension and respiratory depression compared to phenobarbital or propofol, making it safer for non-intubated patients 6